Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease
Stefan Traussnigg, Michael Trauner(Medical University of Vienna), Karl Kashofer(Medical University of Graz), Michael Wolzt(University of California System), Emina Halilbasic(Medical University of Vienna), Günter Fauler(Medical University of Graz), Petra Munda(Medical University of Vienna), Tatjana Stojaković, Harald Hofer(Klinikum Wels-Grieskirchen), Martin Krššák(Christian Doppler Laboratory for Thermoelectricity)
Cited by 41
Related Papers
Simplified criteria for the diagnosis of autoimmune hepatitis†
|Hepatology|2008|1.9k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Cognitive impairment by antibiotic-induced gut dysbiosis: Analysis of gut microbiota-brain communication
|Brain Behavior and Immunity|2016|741